nodes	percent_of_prediction	percent_of_DWPC	metapath
Lubiprostone—CBR1—Doxorubicin—pancreatic cancer	0.762	1	CbGbCtD
Lubiprostone—CLCN2—Ion channel transport—FXYD3—pancreatic cancer	0.00499	0.268	CbGpPWpGaD
Lubiprostone—CBR1—Azacitidine—Gemcitabine—pancreatic cancer	0.00482	1	CbGdCrCtD
Lubiprostone—CBR1—NRF2 pathway—FGF13—pancreatic cancer	0.00273	0.147	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.00174	0.0932	CbGpPWpGaD
Lubiprostone—CBR1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—pancreatic cancer	0.00156	0.0838	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.00142	0.076	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—NFE2L2—pancreatic cancer	0.000766	0.0411	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—TGFA—pancreatic cancer	0.000731	0.0392	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—SLC2A2—pancreatic cancer	0.000716	0.0384	CbGpPWpGaD
Lubiprostone—CBR1—Arachidonic acid metabolism—PTGS2—pancreatic cancer	0.000564	0.0303	CbGpPWpGaD
Lubiprostone—CBR1—NRF2 pathway—HSPA1A—pancreatic cancer	0.00055	0.0295	CbGpPWpGaD
Lubiprostone—CLCN2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000535	0.0287	CbGpPWpGaD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.000483	0.00225	CcSEcCtD
Lubiprostone—Asthenia—Erlotinib—pancreatic cancer	0.000481	0.00224	CcSEcCtD
Lubiprostone—Discomfort—Gemcitabine—pancreatic cancer	0.00048	0.00224	CcSEcCtD
Lubiprostone—Oedema—Irinotecan—pancreatic cancer	0.000478	0.00223	CcSEcCtD
Lubiprostone—Myalgia—Fluorouracil—pancreatic cancer	0.000478	0.00223	CcSEcCtD
Lubiprostone—Chest pain—Fluorouracil—pancreatic cancer	0.000478	0.00223	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.000475	0.00221	CcSEcCtD
Lubiprostone—Discomfort—Fluorouracil—pancreatic cancer	0.000472	0.0022	CcSEcCtD
Lubiprostone—Shock—Irinotecan—pancreatic cancer	0.000471	0.00219	CcSEcCtD
Lubiprostone—Nervous system disorder—Irinotecan—pancreatic cancer	0.000469	0.00219	CcSEcCtD
Lubiprostone—Oedema—Gemcitabine—pancreatic cancer	0.000466	0.00217	CcSEcCtD
Lubiprostone—Diarrhoea—Tamoxifen—pancreatic cancer	0.000464	0.00216	CcSEcCtD
Lubiprostone—Lethargy—Epirubicin—pancreatic cancer	0.000463	0.00216	CcSEcCtD
Lubiprostone—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000463	0.00216	CcSEcCtD
Lubiprostone—Abdominal pain—Sunitinib—pancreatic cancer	0.000459	0.00214	CcSEcCtD
Lubiprostone—Diarrhoea—Erlotinib—pancreatic cancer	0.000459	0.00214	CcSEcCtD
Lubiprostone—Oedema peripheral—Docetaxel—pancreatic cancer	0.000459	0.00214	CcSEcCtD
Lubiprostone—Oedema—Fluorouracil—pancreatic cancer	0.000458	0.00214	CcSEcCtD
Lubiprostone—Connective tissue disorder—Docetaxel—pancreatic cancer	0.000457	0.00213	CcSEcCtD
Lubiprostone—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000457	0.00213	CcSEcCtD
Lubiprostone—Anorexia—Irinotecan—pancreatic cancer	0.000456	0.00213	CcSEcCtD
Lubiprostone—Skin disorder—Gemcitabine—pancreatic cancer	0.000453	0.00211	CcSEcCtD
Lubiprostone—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000451	0.0021	CcSEcCtD
Lubiprostone—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000449	0.00209	CcSEcCtD
Lubiprostone—Dizziness—Tamoxifen—pancreatic cancer	0.000448	0.00209	CcSEcCtD
Lubiprostone—Tachycardia—Fluorouracil—pancreatic cancer	0.000447	0.00208	CcSEcCtD
Lubiprostone—Anorexia—Gemcitabine—pancreatic cancer	0.000444	0.00207	CcSEcCtD
Lubiprostone—Dizziness—Erlotinib—pancreatic cancer	0.000444	0.00207	CcSEcCtD
Lubiprostone—Anorexia—Fluorouracil—pancreatic cancer	0.000437	0.00204	CcSEcCtD
Lubiprostone—Vomiting—Tamoxifen—pancreatic cancer	0.000431	0.00201	CcSEcCtD
Lubiprostone—Lethargy—Doxorubicin—pancreatic cancer	0.000429	0.002	CcSEcCtD
Lubiprostone—Hypersensitivity—Sunitinib—pancreatic cancer	0.000428	0.00199	CcSEcCtD
Lubiprostone—Rash—Tamoxifen—pancreatic cancer	0.000428	0.00199	CcSEcCtD
Lubiprostone—Dermatitis—Tamoxifen—pancreatic cancer	0.000427	0.00199	CcSEcCtD
Lubiprostone—Vomiting—Erlotinib—pancreatic cancer	0.000427	0.00199	CcSEcCtD
Lubiprostone—Dyspnoea—Irinotecan—pancreatic cancer	0.000427	0.00199	CcSEcCtD
Lubiprostone—Headache—Tamoxifen—pancreatic cancer	0.000425	0.00198	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000425	0.00198	CcSEcCtD
Lubiprostone—Rash—Erlotinib—pancreatic cancer	0.000423	0.00197	CcSEcCtD
Lubiprostone—Dermatitis—Erlotinib—pancreatic cancer	0.000423	0.00197	CcSEcCtD
Lubiprostone—Dyspepsia—Irinotecan—pancreatic cancer	0.000421	0.00196	CcSEcCtD
Lubiprostone—Headache—Erlotinib—pancreatic cancer	0.00042	0.00196	CcSEcCtD
Lubiprostone—Mediastinal disorder—Docetaxel—pancreatic cancer	0.00042	0.00195	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000417	0.00195	CcSEcCtD
Lubiprostone—Asthenia—Sunitinib—pancreatic cancer	0.000417	0.00194	CcSEcCtD
Lubiprostone—Decreased appetite—Irinotecan—pancreatic cancer	0.000416	0.00194	CcSEcCtD
Lubiprostone—Dyspnoea—Gemcitabine—pancreatic cancer	0.000416	0.00194	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000413	0.00192	CcSEcCtD
Lubiprostone—Fatigue—Irinotecan—pancreatic cancer	0.000413	0.00192	CcSEcCtD
Lubiprostone—Constipation—Irinotecan—pancreatic cancer	0.000409	0.00191	CcSEcCtD
Lubiprostone—Pain—Irinotecan—pancreatic cancer	0.000409	0.00191	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000409	0.0019	CcSEcCtD
Lubiprostone—Dyspnoea—Fluorouracil—pancreatic cancer	0.000409	0.0019	CcSEcCtD
Lubiprostone—Mental disorder—Docetaxel—pancreatic cancer	0.000408	0.0019	CcSEcCtD
Lubiprostone—Malnutrition—Docetaxel—pancreatic cancer	0.000405	0.00189	CcSEcCtD
Lubiprostone—Erythema—Docetaxel—pancreatic cancer	0.000405	0.00189	CcSEcCtD
Lubiprostone—Decreased appetite—Gemcitabine—pancreatic cancer	0.000405	0.00189	CcSEcCtD
Lubiprostone—Dyspepsia—Fluorouracil—pancreatic cancer	0.000403	0.00188	CcSEcCtD
Lubiprostone—Nausea—Tamoxifen—pancreatic cancer	0.000403	0.00188	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000402	0.00187	CcSEcCtD
Lubiprostone—Fatigue—Gemcitabine—pancreatic cancer	0.000402	0.00187	CcSEcCtD
Lubiprostone—Gastritis—Epirubicin—pancreatic cancer	0.000402	0.00187	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.0004	0.00187	CcSEcCtD
Lubiprostone—Pain—Gemcitabine—pancreatic cancer	0.000399	0.00186	CcSEcCtD
Lubiprostone—Constipation—Gemcitabine—pancreatic cancer	0.000399	0.00186	CcSEcCtD
Lubiprostone—Nausea—Erlotinib—pancreatic cancer	0.000399	0.00186	CcSEcCtD
Lubiprostone—Decreased appetite—Fluorouracil—pancreatic cancer	0.000398	0.00186	CcSEcCtD
Lubiprostone—Diarrhoea—Sunitinib—pancreatic cancer	0.000397	0.00185	CcSEcCtD
Lubiprostone—Dysgeusia—Docetaxel—pancreatic cancer	0.000397	0.00185	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000396	0.00184	CcSEcCtD
Lubiprostone—Abdominal distension—Epirubicin—pancreatic cancer	0.000395	0.00184	CcSEcCtD
Lubiprostone—Feeling abnormal—Irinotecan—pancreatic cancer	0.000394	0.00184	CcSEcCtD
Lubiprostone—Influenza—Epirubicin—pancreatic cancer	0.000392	0.00183	CcSEcCtD
Lubiprostone—Pain—Fluorouracil—pancreatic cancer	0.000392	0.00183	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000391	0.00182	CcSEcCtD
Lubiprostone—Muscle spasms—Docetaxel—pancreatic cancer	0.00039	0.00182	CcSEcCtD
Lubiprostone—Dizziness—Sunitinib—pancreatic cancer	0.000384	0.00179	CcSEcCtD
Lubiprostone—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000384	0.00179	CcSEcCtD
Lubiprostone—Abdominal pain—Irinotecan—pancreatic cancer	0.000378	0.00176	CcSEcCtD
Lubiprostone—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000378	0.00176	CcSEcCtD
Lubiprostone—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000378	0.00176	CcSEcCtD
Lubiprostone—Gastritis—Doxorubicin—pancreatic cancer	0.000372	0.00173	CcSEcCtD
Lubiprostone—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.00037	0.00173	CcSEcCtD
Lubiprostone—Vomiting—Sunitinib—pancreatic cancer	0.000369	0.00172	CcSEcCtD
Lubiprostone—Rash—Sunitinib—pancreatic cancer	0.000366	0.00171	CcSEcCtD
Lubiprostone—Dermatitis—Sunitinib—pancreatic cancer	0.000366	0.0017	CcSEcCtD
Lubiprostone—Abdominal distension—Doxorubicin—pancreatic cancer	0.000365	0.0017	CcSEcCtD
Lubiprostone—Headache—Sunitinib—pancreatic cancer	0.000364	0.0017	CcSEcCtD
Lubiprostone—Syncope—Docetaxel—pancreatic cancer	0.000363	0.00169	CcSEcCtD
Lubiprostone—Influenza—Doxorubicin—pancreatic cancer	0.000363	0.00169	CcSEcCtD
Lubiprostone—Pollakiuria—Epirubicin—pancreatic cancer	0.000362	0.00169	CcSEcCtD
Lubiprostone—Palpitations—Docetaxel—pancreatic cancer	0.000358	0.00167	CcSEcCtD
Lubiprostone—Weight increased—Epirubicin—pancreatic cancer	0.000357	0.00166	CcSEcCtD
Lubiprostone—Loss of consciousness—Docetaxel—pancreatic cancer	0.000356	0.00166	CcSEcCtD
Lubiprostone—Cough—Docetaxel—pancreatic cancer	0.000354	0.00165	CcSEcCtD
Lubiprostone—Hypersensitivity—Irinotecan—pancreatic cancer	0.000353	0.00164	CcSEcCtD
Lubiprostone—Chest pain—Docetaxel—pancreatic cancer	0.000345	0.00161	CcSEcCtD
Lubiprostone—Myalgia—Docetaxel—pancreatic cancer	0.000345	0.00161	CcSEcCtD
Lubiprostone—Nausea—Sunitinib—pancreatic cancer	0.000345	0.00161	CcSEcCtD
Lubiprostone—Asthenia—Irinotecan—pancreatic cancer	0.000343	0.0016	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000343	0.0016	CcSEcCtD
Lubiprostone—Urinary tract infection—Epirubicin—pancreatic cancer	0.00034	0.00158	CcSEcCtD
Lubiprostone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000338	0.00157	CcSEcCtD
Lubiprostone—Dry mouth—Docetaxel—pancreatic cancer	0.000337	0.00157	CcSEcCtD
Lubiprostone—Pollakiuria—Doxorubicin—pancreatic cancer	0.000335	0.00156	CcSEcCtD
Lubiprostone—Asthenia—Gemcitabine—pancreatic cancer	0.000334	0.00156	CcSEcCtD
Lubiprostone—Oedema—Docetaxel—pancreatic cancer	0.000331	0.00154	CcSEcCtD
Lubiprostone—Weight increased—Doxorubicin—pancreatic cancer	0.00033	0.00154	CcSEcCtD
Lubiprostone—Diarrhoea—Irinotecan—pancreatic cancer	0.000327	0.00153	CcSEcCtD
Lubiprostone—Shock—Docetaxel—pancreatic cancer	0.000325	0.00152	CcSEcCtD
Lubiprostone—Nervous system disorder—Docetaxel—pancreatic cancer	0.000324	0.00151	CcSEcCtD
Lubiprostone—Tachycardia—Docetaxel—pancreatic cancer	0.000323	0.0015	CcSEcCtD
Lubiprostone—Skin disorder—Docetaxel—pancreatic cancer	0.000321	0.0015	CcSEcCtD
Lubiprostone—Diarrhoea—Gemcitabine—pancreatic cancer	0.000319	0.00149	CcSEcCtD
Lubiprostone—Dizziness—Irinotecan—pancreatic cancer	0.000316	0.00147	CcSEcCtD
Lubiprostone—Anorexia—Docetaxel—pancreatic cancer	0.000315	0.00147	CcSEcCtD
Lubiprostone—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000315	0.00147	CcSEcCtD
Lubiprostone—Diarrhoea—Fluorouracil—pancreatic cancer	0.000314	0.00146	CcSEcCtD
Lubiprostone—Oedema peripheral—Epirubicin—pancreatic cancer	0.000309	0.00144	CcSEcCtD
Lubiprostone—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000309	0.00144	CcSEcCtD
Lubiprostone—Vomiting—Irinotecan—pancreatic cancer	0.000304	0.00142	CcSEcCtD
Lubiprostone—Dizziness—Fluorouracil—pancreatic cancer	0.000303	0.00141	CcSEcCtD
Lubiprostone—Rash—Irinotecan—pancreatic cancer	0.000302	0.00141	CcSEcCtD
Lubiprostone—Dermatitis—Irinotecan—pancreatic cancer	0.000301	0.0014	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000301	0.0014	CcSEcCtD
Lubiprostone—Headache—Irinotecan—pancreatic cancer	0.0003	0.0014	CcSEcCtD
Lubiprostone—Vomiting—Gemcitabine—pancreatic cancer	0.000296	0.00138	CcSEcCtD
Lubiprostone—Dyspnoea—Docetaxel—pancreatic cancer	0.000295	0.00137	CcSEcCtD
Lubiprostone—Rash—Gemcitabine—pancreatic cancer	0.000294	0.00137	CcSEcCtD
Lubiprostone—Dermatitis—Gemcitabine—pancreatic cancer	0.000294	0.00137	CcSEcCtD
Lubiprostone—Headache—Gemcitabine—pancreatic cancer	0.000292	0.00136	CcSEcCtD
Lubiprostone—Vomiting—Fluorouracil—pancreatic cancer	0.000291	0.00136	CcSEcCtD
Lubiprostone—Dyspepsia—Docetaxel—pancreatic cancer	0.000291	0.00136	CcSEcCtD
Lubiprostone—Rash—Fluorouracil—pancreatic cancer	0.000289	0.00135	CcSEcCtD
Lubiprostone—Dermatitis—Fluorouracil—pancreatic cancer	0.000289	0.00135	CcSEcCtD
Lubiprostone—Decreased appetite—Docetaxel—pancreatic cancer	0.000288	0.00134	CcSEcCtD
Lubiprostone—Headache—Fluorouracil—pancreatic cancer	0.000287	0.00134	CcSEcCtD
Lubiprostone—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000286	0.00133	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000286	0.00133	CcSEcCtD
Lubiprostone—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000286	0.00133	CcSEcCtD
Lubiprostone—Fatigue—Docetaxel—pancreatic cancer	0.000285	0.00133	CcSEcCtD
Lubiprostone—Nausea—Irinotecan—pancreatic cancer	0.000284	0.00132	CcSEcCtD
Lubiprostone—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000283	0.00132	CcSEcCtD
Lubiprostone—Constipation—Docetaxel—pancreatic cancer	0.000283	0.00132	CcSEcCtD
Lubiprostone—Pain—Docetaxel—pancreatic cancer	0.000283	0.00132	CcSEcCtD
Lubiprostone—Nausea—Gemcitabine—pancreatic cancer	0.000277	0.00129	CcSEcCtD
Lubiprostone—Mental disorder—Epirubicin—pancreatic cancer	0.000275	0.00128	CcSEcCtD
Lubiprostone—Erythema—Epirubicin—pancreatic cancer	0.000273	0.00127	CcSEcCtD
Lubiprostone—Malnutrition—Epirubicin—pancreatic cancer	0.000273	0.00127	CcSEcCtD
Lubiprostone—Feeling abnormal—Docetaxel—pancreatic cancer	0.000273	0.00127	CcSEcCtD
Lubiprostone—Nausea—Fluorouracil—pancreatic cancer	0.000272	0.00127	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00027	0.00126	CcSEcCtD
Lubiprostone—Flatulence—Epirubicin—pancreatic cancer	0.000269	0.00126	CcSEcCtD
Lubiprostone—Dysgeusia—Epirubicin—pancreatic cancer	0.000268	0.00125	CcSEcCtD
Lubiprostone—Muscle spasms—Epirubicin—pancreatic cancer	0.000263	0.00122	CcSEcCtD
Lubiprostone—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000262	0.00122	CcSEcCtD
Lubiprostone—Abdominal pain—Docetaxel—pancreatic cancer	0.000261	0.00122	CcSEcCtD
Lubiprostone—Mental disorder—Doxorubicin—pancreatic cancer	0.000255	0.00119	CcSEcCtD
Lubiprostone—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000254	0.00118	CcSEcCtD
Lubiprostone—Erythema—Doxorubicin—pancreatic cancer	0.000253	0.00118	CcSEcCtD
Lubiprostone—Malnutrition—Doxorubicin—pancreatic cancer	0.000253	0.00118	CcSEcCtD
Lubiprostone—Flatulence—Doxorubicin—pancreatic cancer	0.000249	0.00116	CcSEcCtD
Lubiprostone—Dysgeusia—Doxorubicin—pancreatic cancer	0.000248	0.00115	CcSEcCtD
Lubiprostone—Malaise—Epirubicin—pancreatic cancer	0.000247	0.00115	CcSEcCtD
Lubiprostone—Syncope—Epirubicin—pancreatic cancer	0.000245	0.00114	CcSEcCtD
Lubiprostone—Hypersensitivity—Docetaxel—pancreatic cancer	0.000244	0.00114	CcSEcCtD
Lubiprostone—Muscle spasms—Doxorubicin—pancreatic cancer	0.000243	0.00113	CcSEcCtD
Lubiprostone—Palpitations—Epirubicin—pancreatic cancer	0.000242	0.00113	CcSEcCtD
Lubiprostone—Loss of consciousness—Epirubicin—pancreatic cancer	0.00024	0.00112	CcSEcCtD
Lubiprostone—Cough—Epirubicin—pancreatic cancer	0.000239	0.00111	CcSEcCtD
Lubiprostone—Asthenia—Docetaxel—pancreatic cancer	0.000237	0.00111	CcSEcCtD
Lubiprostone—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000235	0.00109	CcSEcCtD
Lubiprostone—Myalgia—Epirubicin—pancreatic cancer	0.000233	0.00108	CcSEcCtD
Lubiprostone—Chest pain—Epirubicin—pancreatic cancer	0.000233	0.00108	CcSEcCtD
Lubiprostone—Anxiety—Epirubicin—pancreatic cancer	0.000232	0.00108	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000231	0.00108	CcSEcCtD
Lubiprostone—Discomfort—Epirubicin—pancreatic cancer	0.00023	0.00107	CcSEcCtD
Lubiprostone—Malaise—Doxorubicin—pancreatic cancer	0.000228	0.00106	CcSEcCtD
Lubiprostone—Dry mouth—Epirubicin—pancreatic cancer	0.000228	0.00106	CcSEcCtD
Lubiprostone—Syncope—Doxorubicin—pancreatic cancer	0.000227	0.00106	CcSEcCtD
Lubiprostone—Diarrhoea—Docetaxel—pancreatic cancer	0.000226	0.00105	CcSEcCtD
Lubiprostone—Palpitations—Doxorubicin—pancreatic cancer	0.000224	0.00104	CcSEcCtD
Lubiprostone—Oedema—Epirubicin—pancreatic cancer	0.000223	0.00104	CcSEcCtD
Lubiprostone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000222	0.00104	CcSEcCtD
Lubiprostone—Cough—Doxorubicin—pancreatic cancer	0.000221	0.00103	CcSEcCtD
Lubiprostone—Shock—Epirubicin—pancreatic cancer	0.000219	0.00102	CcSEcCtD
Lubiprostone—Nervous system disorder—Epirubicin—pancreatic cancer	0.000219	0.00102	CcSEcCtD
Lubiprostone—Dizziness—Docetaxel—pancreatic cancer	0.000219	0.00102	CcSEcCtD
Lubiprostone—Tachycardia—Epirubicin—pancreatic cancer	0.000218	0.00101	CcSEcCtD
Lubiprostone—Skin disorder—Epirubicin—pancreatic cancer	0.000217	0.00101	CcSEcCtD
Lubiprostone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000216	0.001	CcSEcCtD
Lubiprostone—Chest pain—Doxorubicin—pancreatic cancer	0.000215	0.001	CcSEcCtD
Lubiprostone—Myalgia—Doxorubicin—pancreatic cancer	0.000215	0.001	CcSEcCtD
Lubiprostone—Anxiety—Doxorubicin—pancreatic cancer	0.000215	0.001	CcSEcCtD
Lubiprostone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000214	0.000996	CcSEcCtD
Lubiprostone—Discomfort—Doxorubicin—pancreatic cancer	0.000213	0.000991	CcSEcCtD
Lubiprostone—Anorexia—Epirubicin—pancreatic cancer	0.000213	0.000991	CcSEcCtD
Lubiprostone—Dry mouth—Doxorubicin—pancreatic cancer	0.000211	0.000981	CcSEcCtD
Lubiprostone—Vomiting—Docetaxel—pancreatic cancer	0.00021	0.00098	CcSEcCtD
Lubiprostone—Rash—Docetaxel—pancreatic cancer	0.000209	0.000972	CcSEcCtD
Lubiprostone—Dermatitis—Docetaxel—pancreatic cancer	0.000208	0.000971	CcSEcCtD
Lubiprostone—Headache—Docetaxel—pancreatic cancer	0.000207	0.000965	CcSEcCtD
Lubiprostone—Oedema—Doxorubicin—pancreatic cancer	0.000206	0.000962	CcSEcCtD
Lubiprostone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000203	0.000947	CcSEcCtD
Lubiprostone—Shock—Doxorubicin—pancreatic cancer	0.000203	0.000946	CcSEcCtD
Lubiprostone—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000202	0.000943	CcSEcCtD
Lubiprostone—Tachycardia—Doxorubicin—pancreatic cancer	0.000201	0.000939	CcSEcCtD
Lubiprostone—Skin disorder—Doxorubicin—pancreatic cancer	0.0002	0.000934	CcSEcCtD
Lubiprostone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.0002	0.00093	CcSEcCtD
Lubiprostone—Dyspnoea—Epirubicin—pancreatic cancer	0.000199	0.000927	CcSEcCtD
Lubiprostone—Anorexia—Doxorubicin—pancreatic cancer	0.000197	0.000917	CcSEcCtD
Lubiprostone—Nausea—Docetaxel—pancreatic cancer	0.000196	0.000915	CcSEcCtD
Lubiprostone—Dyspepsia—Epirubicin—pancreatic cancer	0.000196	0.000915	CcSEcCtD
Lubiprostone—Decreased appetite—Epirubicin—pancreatic cancer	0.000194	0.000904	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000193	0.000897	CcSEcCtD
Lubiprostone—Fatigue—Epirubicin—pancreatic cancer	0.000192	0.000896	CcSEcCtD
Lubiprostone—Pain—Epirubicin—pancreatic cancer	0.000191	0.000889	CcSEcCtD
Lubiprostone—Constipation—Epirubicin—pancreatic cancer	0.000191	0.000889	CcSEcCtD
Lubiprostone—CBR1—Metabolism—PRSS1—pancreatic cancer	0.000188	0.0101	CbGpPWpGaD
Lubiprostone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000188	0.000876	CcSEcCtD
Lubiprostone—Dyspnoea—Doxorubicin—pancreatic cancer	0.000184	0.000857	CcSEcCtD
Lubiprostone—Feeling abnormal—Epirubicin—pancreatic cancer	0.000184	0.000857	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000182	0.00085	CcSEcCtD
Lubiprostone—Dyspepsia—Doxorubicin—pancreatic cancer	0.000182	0.000847	CcSEcCtD
Lubiprostone—Decreased appetite—Doxorubicin—pancreatic cancer	0.000179	0.000836	CcSEcCtD
Lubiprostone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000178	0.00083	CcSEcCtD
Lubiprostone—Fatigue—Doxorubicin—pancreatic cancer	0.000178	0.000829	CcSEcCtD
Lubiprostone—Pain—Doxorubicin—pancreatic cancer	0.000177	0.000822	CcSEcCtD
Lubiprostone—Constipation—Doxorubicin—pancreatic cancer	0.000177	0.000822	CcSEcCtD
Lubiprostone—Abdominal pain—Epirubicin—pancreatic cancer	0.000176	0.000822	CcSEcCtD
Lubiprostone—CBR1—NRF2 pathway—TGFB1—pancreatic cancer	0.000173	0.00929	CbGpPWpGaD
Lubiprostone—Feeling abnormal—Doxorubicin—pancreatic cancer	0.00017	0.000793	CcSEcCtD
Lubiprostone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000169	0.000786	CcSEcCtD
Lubiprostone—Hypersensitivity—Epirubicin—pancreatic cancer	0.000164	0.000766	CcSEcCtD
Lubiprostone—Abdominal pain—Doxorubicin—pancreatic cancer	0.000163	0.00076	CcSEcCtD
Lubiprostone—CBR1—Metabolism—ARG2—pancreatic cancer	0.000163	0.00875	CbGpPWpGaD
Lubiprostone—Asthenia—Epirubicin—pancreatic cancer	0.00016	0.000746	CcSEcCtD
Lubiprostone—Diarrhoea—Epirubicin—pancreatic cancer	0.000153	0.000711	CcSEcCtD
Lubiprostone—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000152	0.000709	CcSEcCtD
Lubiprostone—Asthenia—Doxorubicin—pancreatic cancer	0.000148	0.00069	CcSEcCtD
Lubiprostone—Dizziness—Epirubicin—pancreatic cancer	0.000148	0.000687	CcSEcCtD
Lubiprostone—CBR1—Metabolism—TYMP—pancreatic cancer	0.000143	0.00765	CbGpPWpGaD
Lubiprostone—Vomiting—Epirubicin—pancreatic cancer	0.000142	0.000661	CcSEcCtD
Lubiprostone—Diarrhoea—Doxorubicin—pancreatic cancer	0.000141	0.000658	CcSEcCtD
Lubiprostone—Rash—Epirubicin—pancreatic cancer	0.000141	0.000655	CcSEcCtD
Lubiprostone—Dermatitis—Epirubicin—pancreatic cancer	0.000141	0.000655	CcSEcCtD
Lubiprostone—Headache—Epirubicin—pancreatic cancer	0.00014	0.000651	CcSEcCtD
Lubiprostone—Dizziness—Doxorubicin—pancreatic cancer	0.000136	0.000636	CcSEcCtD
Lubiprostone—Nausea—Epirubicin—pancreatic cancer	0.000133	0.000617	CcSEcCtD
Lubiprostone—Vomiting—Doxorubicin—pancreatic cancer	0.000131	0.000612	CcSEcCtD
Lubiprostone—Rash—Doxorubicin—pancreatic cancer	0.00013	0.000606	CcSEcCtD
Lubiprostone—Dermatitis—Doxorubicin—pancreatic cancer	0.00013	0.000606	CcSEcCtD
Lubiprostone—Headache—Doxorubicin—pancreatic cancer	0.000129	0.000603	CcSEcCtD
Lubiprostone—Nausea—Doxorubicin—pancreatic cancer	0.000123	0.000571	CcSEcCtD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	0.000118	0.00631	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GLP1R—pancreatic cancer	0.000115	0.00617	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—DPYD—pancreatic cancer	0.000113	0.00607	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—SLC2A2—pancreatic cancer	0.000107	0.00576	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	0.000106	0.0057	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	0.000103	0.0055	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	9.34e-05	0.00501	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—CD44—pancreatic cancer	8.31e-05	0.00446	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	8.14e-05	0.00437	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	8.06e-05	0.00433	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—GCG—pancreatic cancer	7.97e-05	0.00427	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—STK11—pancreatic cancer	7.49e-05	0.00402	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.03e-05	0.00377	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—TYMS—pancreatic cancer	6.44e-05	0.00346	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—APOE—pancreatic cancer	5.24e-05	0.00281	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.96e-05	0.00266	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CG—pancreatic cancer	4.73e-05	0.00254	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PPARG—pancreatic cancer	4.57e-05	0.00245	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CD—pancreatic cancer	4.16e-05	0.00223	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CB—pancreatic cancer	3.62e-05	0.00194	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTGS2—pancreatic cancer	3.59e-05	0.00193	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PTEN—pancreatic cancer	3.13e-05	0.00168	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—PIK3CA—pancreatic cancer	2.21e-05	0.00119	CbGpPWpGaD
Lubiprostone—CBR1—Metabolism—AKT1—pancreatic cancer	1.81e-05	0.000968	CbGpPWpGaD
